CCR5 and metabolic dysfunction-associated steatohepatitis: Thus, treatment of NASH models by using cenicriviroc, an oral dual chemokine receptor CCR2/CCR5 antagonist, reduced infiltration of monocyte-derived macrophages, and ameliorated histological NASH activity and hepatic fibrosis [264].